Skip to main content

Published locations for T2D: Dapagliflozin consistently reduces CV and kidney disease risk irrespective of background therapy

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. T2D: Dapagliflozin consistently reduces CV and kidney disease risk irrespective of background therapy

User login

  • Reset your password
  • /content/t2d-dapagliflozin-consistently-reduces-cv-and-kidney-disease-risk-irrespective-background
  • /type-2-diabetes-icymi/article/257489/diabetes/t2d-dapagliflozin-consistently-reduces-cv-and-kidney